TCW Group’s Moderna MRNA Stock Holding History

TCW Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.15M	Buy	5,983 +26	+0.4%	+$2.8K	0.01%	321
2026 Q2	$417K	Buy	5,957 +254	+4%	+$13.1K	﹤0.01%	534
2026 Q1	$290K	Buy	+5,703	New	+$266K	﹤0.01%	579

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Theleme Partners London, United Kingdom $2.62B AUM 125.04% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

TCW Group's MRNA Position: Q3 2026 in Review

TCW Group increased its Moderna (MRNA) stake by 0.44% in Q3 2026, buying an estimated $2.8K and bringing the position to 5,983 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #321.

TCW Group first reported a position in MRNA in Q1 2026 and has held it in 3 quarters since. 858 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

TCW Group held 5,983 shares of Moderna worth $1.15M as of Q3 2026.
TCW Group bought 26 Moderna shares in Q3 2026, an estimated $2.8K.
Moderna made up 0.01% of TCW Group's portfolio in Q3 2026, its #321 holding.
TCW Group first reported a position in Moderna in Q1 2026 and has held it in 3 quarters since.
858 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on TCW Group's 13F filing for Q3 2026, filed 10 Nov 2026.